EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Advancing precision oncology through systematic germline and tumor genetic analysis: The oncogenetic point of view on findings from a prospective multicenter clinical trial of 666 patients

Benoit Mazel iD, Geoffrey Bertolone, Amandine Baurand, Elodie Cosset, Caroline Sawka, Marion Robert, Elodie Gautier, Allan Lançon, Manon Réda, Laure Favier, Valentin Dérangère, Corentin Richard und 7 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.6498 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Benoit Mazel und 18 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Génétique, FHU-TRANSLAD, Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Genetic Testing, Germ-Line Mutation, Neoplasms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centre Georges François Leclerc, Centre Hospitalier Universitaire Dijon-Bourgogne, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

With the emergence of targeted therapies, there is a need to accurately identify more tumor biomarkers. The EXOMA trial was designed to offer tumor and germline exome sequencing (ES) to patients with solid malignant tumors and facing therapeutic failure. As hereditary cancer predispositions could be identified, with genetic counseling and health management implications, a genetic consultation was systematically established. This design needs to be discussed as genetic human resources are limited and indication of theranostic tests will increase.

Methods

Genetic counseling was conducted within 15 days following inclusion in the study for patients recruited between December 2015 and July 2019. In silico analyses from theranostic ES were limited to 317 genes involved in oncogenesis, from both tumor and blood DNA.

Results

Six hundred and sixty six patients had a genetic consultation before ES. In 65/666 patients, 66 germline pathogenic or likely pathogenic (P/LP) variants were identified in 16 actionable genes and seven non‐actionable genes according to French guidelines. 24/65 patients had previously received genetic analysis for diagnostic purposes, and for 17 of them, a P/LP variant had already been identified. Among the 48/65 remaining cases for which the EXOMA protocol revealed a previously unknown P/LP variant, only 19 met the criteria for genetic testing for inherited cancer risk after familial survey. These criteria had not been identified by the oncologist in 10 cases. In 21/65 cases, the variant was considered incidental.

Discussion

In 7.4% of patients, an undiagnosed hereditary genetic predisposition was identified, whether or not related to the clinical presentation, and germline analysis impacted oncological management for only 6.3% of the cohort. This low percentage should be weighed against the burden of systematic genetic consultation and urgent circuits. Information or training tools to form oncologists to the prescription of germline genetic analyses should be explored, as well as information supports and patient preferences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorGenetic TestingGerm-Line MutationNeoplasmsPrecision MedicineAdultAgedFemaleHumansMaleMiddle AgedExome SequencingGenetic CounselingGenetic Predisposition to DiseaseProspective Studies

Stichwörter der Autor:innen

genetic counselingincidental findingsinformationoncogenetictheranostic exome sequencing

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Centre de Génétique, FHU-TRANSLAD, Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France.
  • INSERM UMR 1231 GAD, Génétique des Anomalies du Développement, Université Bourgogne Franche-Comté, Dijon, France.
  • Unité d'Oncogénétique, Centre de Lutte Contre le Cancer Georges François Leclerc-UNICANCER, Dijon, France.
  • Département d'Oncologie Médicale, Centre de Lutte Contre le Cancer Georges François Leclerc-UNICANCER, Dijon, France.
  • Plateforme de Transfert en Biologie Cancérologique, Centre de Lutte Contre le Cancer Georges François Leclerc-UNICANCER, Dijon, France.
  • INSERM UMR 1231 GIMI, Genomic and Immunotherapy Medical Institute, Université Bourgogne Franche-Comté, Dijon, France.

ORCID-Profile: Benoit Mazel, Laurence Faivre

Förderung

  • Centre Georges François Leclerc
  • Centre Hospitalier Universitaire Dijon-Bourgogne
  • European Union
  • European Commission

Zitieren

APA

Mazel, B., Bertolone, G., Baurand, A., Cosset, E., Sawka, C., Robert, M., Gautier, E., Lançon, A., Réda, M., Favier, L., Dérangère, V., Richard, C., Binquet, C., Boidot, R., Goussot, V., Albuisson, J., Ghiringhelli, F., Faivre, L., & Nambot, S. (2023). Advancing precision oncology through systematic germline and tumor genetic analysis: The oncogenetic point of view on findings from a prospective multicenter clinical trial of 666 patients. Cancer Medicine. https://doi.org/10.1002/cam4.6498

Vancouver

Mazel B, Bertolone G, Baurand A, Cosset E, Sawka C, Robert M, et al. Advancing precision oncology through systematic germline and tumor genetic analysis: The oncogenetic point of view on findings from a prospective multicenter clinical trial of 666 patients. Cancer Medicine. 2023. doi:10.1002/cam4.6498

BibTeX
@article{Mazel2023,
  author = {Mazel, Benoit and Bertolone, Geoffrey and Baurand, Amandine and Cosset, Elodie and Sawka, Caroline and Robert, Marion and Gautier, Elodie and Lançon, Allan and Réda, Manon and Favier, Laure and Dérangère, Valentin and Richard, Corentin and Binquet, Christine and Boidot, Romain and Goussot, Vincent and Albuisson, Juliette and Ghiringhelli, François and Faivre, Laurence and Nambot, Sophie},
  title = {Advancing precision oncology through systematic germline and tumor genetic analysis: The oncogenetic point of view on findings from a prospective multicenter clinical trial of 666 patients},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6498}
}
Kostenlos starten →